High-dose insulin therapy: is it time for U-500 insulin?
about
Concentrated insulins: the new basal insulinsU-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients.U-500 insulin as a component of basal bolus insulin therapy in type 2 diabetes.Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study.A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections.Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjectsInitiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort studyMild Caloric Restriction Decreases Insulin Requirements in Patients With Type 2 Diabetes and Severe Insulin Resistance.Clinical use of U-500 regular insulin: review and meta-analysis.Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin.Treatment Approach to Patients With Severe Insulin Resistance.Adequate prescribing of medication does not necessarily translate into good control of diabetes mellitus.Learning about new therapies: phase 3 clinical studies--and beyond.Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-taPatient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial.The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.Extreme insulin resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus.Evolution of insulin development: focus on key parameters.The use of U-500 regular insulin in the management of patients with obesity and insulin resistance.Practice tips and tools for the successful use of U-500 regular human insulin: the diabetes educator is key.A practical guide to concentrated insulin for pharmacists.Clinical considerations for insulin pharmacotherapy in ambulatory care, part two: review of primary literature and an evidence-based approach for treatment.Pharmacologic treatment of type 2 diabetes: injectable medications.Management of Severe Insulin Resistance in Patients with Type 1 Diabetes.A primer on concentrated insulins: what an internist should know.Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of DiabetesHigher concentration insulins: an overview of clinical considerations.Insulin pump use in type 2 diabetes.Translating U-500R Randomized Clinical Trial Evidence to the Practice Setting: A Diabetes Educator/Expert Prescriber Team Approach.Clinical efficacy and patient satisfaction with U-500 insulin use.Use of U-500 regular insulin via continuous subcutaneous insulin infusion: clinical practice experience.Novel Concentrated Insulin Delivery Devices: Developments for Safe and Simple Dose Conversions.U-500R and aspart insulin for the treatment of severe insulin resistance in pregnancy associated with pregestational diabetes.Understanding concentrated insulins: a systematic review of randomized controlled trials.The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin.Delayed Response to U-500 Regular Insulin.
P2860
Q26750438-773D1B28-5B8D-45C5-881C-FBC88E9256CCQ33602161-3DFEE4A4-91B5-4E10-8D5A-B71C5CA3459EQ33869977-71FFD50F-DE37-4166-994F-8B0217DF94DCQ34351640-04EF2794-1BC1-4DA2-8A13-DCADFB6BF21EQ35336944-5FB973E9-3D74-4C8E-B92D-900046651EF9Q35563634-545FF7B1-DB65-4766-9FBE-10F1EF1D781EQ35568834-EEF46BAA-25B3-42F7-AFBD-02C40B463471Q36009397-5F5EF15B-53AA-43CD-BBCB-158AA0E5116EQ36051311-F04E02BB-1B62-445D-97C2-E5E6634F26F4Q36608993-34840596-86A6-4CA8-9454-14CC13D13367Q36803134-2707675D-2858-4FBA-9F5C-464C5BCF4F76Q37015105-952F1A3D-B447-48B4-B389-5ABB0698AA65Q37106427-B808D091-DC40-4EC6-8C0F-DFC2F5698E43Q37106509-AE33A108-52C2-4D26-88F7-748B7095CB46Q37302296-C03AEE04-EB29-4E1B-AB81-0BCF68280F5BQ37502548-98BAC62C-1FF7-4964-96BA-8DDE790BFA64Q37682560-336C81DA-FFF2-486E-A198-AD241C56DC06Q37821348-5E601FF9-692B-4F8A-9991-55F1FF6E35E5Q38030454-21959609-3733-4932-8270-6284A51B2029Q38089255-F4E82107-7F93-4C9F-990C-0619C277EF27Q38155486-D5AF8CDA-B6CA-41BD-98CF-776F3214D7EBQ38265583-6369E7F8-350C-4EE5-A260-8DD554F58E2FQ38344775-F82C9FE4-4410-490A-92E1-54B166B91B73Q38388602-8E624CEF-1942-4144-AD09-CCA615001527Q38570757-DA2727DF-EEEA-40E2-B599-52DE93B16D76Q38754210-2D65848E-5264-4D4D-928A-C74EEEAB432CQ38811608-DE33DF1F-09B5-463C-BA09-BE1F3B476054Q39285855-6AB2C2E9-6E3F-4436-9DFB-583AD5759829Q39865848-4BBD7B0E-84BF-4F65-8803-7ED9B90041CFQ41963319-B0C89F29-E012-45C0-8B0B-6FAD30111568Q42100513-67A70191-B048-4013-9D8E-AD0769C7693BQ42938553-D94DE139-857A-4DCB-AFE4-24E9D75D3870Q44372707-3C10FA50-DB21-423E-B70F-40220E59D44BQ44820539-5413DC19-1E5B-4D32-A0EA-521CF48490EAQ47322851-D3CBED38-CFC0-4F75-8332-1701D2A83374Q48287418-0D017C80-A626-43FF-84CD-C77E884485D6Q49570450-8C7383EF-3395-40A6-B469-7A6757E868D1
P2860
High-dose insulin therapy: is it time for U-500 insulin?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
High-dose insulin therapy: is it time for U-500 insulin?
@en
High-dose insulin therapy: is it time for U-500 insulin?
@nl
type
label
High-dose insulin therapy: is it time for U-500 insulin?
@en
High-dose insulin therapy: is it time for U-500 insulin?
@nl
prefLabel
High-dose insulin therapy: is it time for U-500 insulin?
@en
High-dose insulin therapy: is it time for U-500 insulin?
@nl
P2093
P356
P1433
P1476
High-dose insulin therapy: is it time for U-500 insulin?
@en
P2093
Elaine K Cochran
Ilene B Corey
Irl B Hirsch
Jamie L Scism-Bacon
Jay S Skyler
Jeffrey A Jackson
Wendy S Lane
P356
10.4158/EP.15.1.71
P577
2009-01-01T00:00:00Z